A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection.
Phase of Trial: Phase I
Latest Information Update: 17 May 2015
At a glance
- Drugs Eptinezumab (Primary) ; Eptinezumab (Primary) ; Sumatriptan
- Indications Migraine
- Focus Adverse reactions
- 15 May 2015 According to an Alder Biopharmaceuticals media release, data from this trial were presented at the 17th Congress of the International Headache Society.
- 07 May 2015 According to Alder BioPharmaceuticals media release, data from this trial will be presented at 17th Congress of the International Headache Society.
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.